In the era of smart manufacturing, the development of pharma intermediates is also experiencing new opportunities. Utilizing advanced technologies like big data, artificial intelligence, and continuous flow chemistry, pharmaceutical companies can precisely control synthesis reactions, achieving efficient production of intermediates and customized batches of antibiotics. For example, real-time monitoring of reaction conditions and automatic parameter adjustments can significantly increase the yield and purity of intermediates, reduce by-product formation, and optimize antibiotic production processes.